CoChat
Sign Up
Cited by 125Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesChronic Myeloid Leukemia Treatments

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Open access
Ravandi, Farhad, Kantarjian, Hagop, Faderl, Stefan, Garcia-Manero, Guillermo, O’Brien, Susan, Koller, Charles, Pierce, Sherry, Brandt, Mark +3 more·2010·Leukemia Research
DOI 10.1016/j.leukres.2009.10.001PMC PMC4082769
Open this paper in CoChat — free account

Abstract

Mutations of Fms-like tyrosine kinase-3 (FLT3) have been described in about 30% of patients with acute myeloid leukemia (AML) and are associated with a shorter disease-free and overall survival after initial therapy. We sought to examine whether the presence of these mutations in relapsed disease was also associated with a poor response to salvage chemotherapy by comparing the outcome of 34 patients with diploid cytogenetics and mutated FLT3 (internal tandem duplication mutation, ITD) to 69 patients with normal karyotype and wild-type FLT3 (FLT3-WT) in first relapse. On univariate analysis, patients with mutated FLT3 were less likely to achieve a CR to first salvage compared to FLT3-WT patients (24% vs. 41%; P=0.09). Furthermore, survival was longer for the FLT3-WT patients achieving a second CR after salvage compared to FLT3-mutated patients (P=0.017). Overall, patients with mutated FLT3 had a shorter survival from the time of relapse compared to those with FLT3-WT (P<0.001). The adverse prognostic impact of FLT3 mutations appears to persist beyond the initial treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.leukres.2009.10.001

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Roughly 30% of patients with acute myeloid leukaemia carry FLT3-activating mutations, the presence of which portends poor outcomes.

    “Roughly 30% of patients with acute myeloid leukaemia carry FLT3-activating mutations, the presence of which portends poor outcomes48.”

    From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [48]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 33

  1. [1]Gilliland DG Griffin JD The roles of FLT3 in hematopoiesis and leukemia Blood 2002 9 1 100 5 1532 1542 12176867
  2. [2]Brasel K Escobar S Anderberg R Expression of the flt3 receptor and its ligand on hematopoietic cells Leukemia 1995 7 9 7 1212 1218 7630197
  3. [3]Drexler HG Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells Leukemia 1996 4 10 4 588 599 8618433
  4. [4]Turner AM Lin NL Issarachai S FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells Blood 1996 11 1 88 9 3383 3390 8896403
  5. [5]Birg F Courcoul M Rosnet O Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages Blood 1992 11 15 80 10 2584 2593 1384791
  6. [6]Carow CE Levenstein M Kaufmann SH Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias Blood 1996 2 1 87 3 1089 1096 8562934
  7. [7]Stacchini A Fubini L Severino A Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts Leukemia 1996 10 10 10 1584 1591 8847893
  8. [8]Levis M Small D FLT3: ITDoes matter in leukemia Leukemia 2003 9 17 9 1738 1752 12970773
  9. [9]Nakao M Yokota S Iwai T Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 1996 12 10 12 1911 1918 8946930
  10. [10]Thiede C Steudel C Mohr B Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 2002 6 15 99 12 4326 4335 12036858
  11. [11]Yamamoto Y Kiyoi H Nakano Y Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 2001 4 15 97 8 2434 2439 11290608
  12. [12]Abu-Duhier FM Goodeve AC Wilson GA FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol 2000 10 111 1 190 195 11091200
  13. [13]Abu-Duhier FM Goodeve AC Wilson GA Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia Br J Haematol 2001 6 113 4 983 988 11442493
  14. [14]Frohling S Schlenk RF Breitruck J Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 2002 12 15 100 13 4372 4380 12393388
  15. [15]Kottaridis PD Gale RE Frew ME The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 2001 9 15 98 6 1752 1759 11535508
  16. [16]Meshinchi S Stirewalt DL Alonzo TA Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia Blood 2003 8 15 102 4 1474 1479 12702504
  17. [17]Kiyoi H Naoe T Nakano Y Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 1999 5 1 93 9 3074 3080 10216104
  18. [18]Mead AJ Linch DC Hills RK FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia Blood 2007 8 15 110 4 1262 1270 17456725
  19. [19]Whitman SP Ruppert AS Radmacher MD FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Blood 2008 2 1 111 3 1552 1559 17940205 PMC2214747
  20. [20]Mead AJ Gale RE Hills RK Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease Blood 2008 7 15 112 2 444 445 author reply 445. 18606888 PMC2481522
  21. [21]Kiyoi H Ohno R Ueda R Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene 2002 4 11 21 16 2555 2563 11971190
  22. [22]Levis M Tse KF Smith BD A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations Blood 2001 8 1 98 3 885 887 11468194
  23. [23]Smith BD Levis M Beran M Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 2004 5 15 103 10 3669 3676 14726387
  24. [24]Stone RM DeAngelo DJ Klimek V Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 2004 9 2 15345597
  25. [25]DeAngelo DJ Stone RM Heaney ML Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood 2006 12 1 108 12 3674 3681 16902153 PMC1895460
  26. [26]Mori S Cortes J Kantarjian H Potential role of sorafenib in the treatment of acute myeloid leukemia Leuk Lymphoma 2008 12 49 12 2246 2255 19052971 PMC4086439
  27. [27]Metzelder S Wang Y Wollmer E Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation Blood 2009 6 25 113 26 6567 6571 19389879
  28. [28]Levis M Ravandi F Wang E Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse 2009 PMC3069671 21270442
  29. [29]Kern W Estey EH High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials Cancer 2006 7 1 107 1 116 124 16721819
  30. [30]Estey E Treatment of refractory AML Leukemia 1996 6 10 6 932 936 8667647
  31. [32]Beran M Luthra R Kantarjian H FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype Leuk Res 2004 6 28 6 547 550 15120929
  32. [33]Lin P Jones D Medeiros LJ Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia Am J Clin Pathol 2006 10 126 4 530 533 16938665
  33. [34]Kottaridis PD Gale RE Langabeer SE Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood 2002 10 1 100 7 2393 2398 12239147

Cited by

Sorted by citations

Authors
Ravandi, F., Kantarjian, H., Faderl, S., Garcia-Manero, G., O’Brien, S., Koller, C., Pierce, S., Brandt, M., Kennedy, D., Cortes, J., & Beran, M.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Ravandi, Farhad
ORCID
Venue
Leukemia Research
Publisher
Elsevier BV
Published
2010-06
Volume
34
Issue
6
Pages
752-756
ISSN
0145-2126 (ISSN-L)
DOI
10.1016/j.leukres.2009.10.001
PMC
PMC4082769
OpenAlex
W2060402045
Cited by
125
References
0
Citations by year
2026: 5 · 2025: 4 · 2024: 11 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 15 · 2019: 8 · 2018: 4 · 2017: 4 · 2016: 9 · 2015: 7 · 2014: 6 · 2013: 11 · 2012: 8
FWCI
3.41
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Leukemia Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA016672)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords
FLT3 mutation, acute myeloid leukemia, first relapse, salvage chemotherapy, internal tandem duplication, complete remission, prognosis, survival after relapse
MeSH terms
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Follow-Up Studies, Humans, Middle Aged, Mutation, Prognosis, Recurrence, Cohort Studies, Leukemia, Myeloid, Acute, Survival Analysis, Salvage Therapy, Treatment Outcome, fms-Like Tyrosine Kinase 3, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review